| [1] |
Ito K, Yokota S, Watanabe M, et al. Anemia in diabetic patients reflects severe tubulointerstitial injury and aids in clinically predicting a diagnosis of diabetic nephropathy[J]. Intern Med, 2021, 60(9): 1349-1357.
doi: 10.2169/internalmedicine.5455-20
URL
|
| [2] |
Shams N, Osmani MH. Newly diagnosed anemia in admitted diabetics, frequency, etiology and associated factors[J]. J Coll Physicians Surg Pak, 2015, 25(4): 242-246.
|
| [3] |
Miulescu RD, Neamtu MC, Margină D, et al. Associations between thyroid dysfunction and chronic kidney disease[J]. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2014, 21(1): 37-42.
doi: 10.2478/rjdnmd-2014-0006
URL
|
| [4] |
Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease[J]. Indian J Endocrinol Metab, 2012, 16(2): 204-213.
doi: 10.4103/2230-8210.93737
pmid: 22470856
|
| [5] |
Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994)[J]. Arch Intern Med, 2002, 162(12): 1401-1408.
doi: 10.1001/archinte.162.12.1401
pmid: 12076240
|
| [6] |
许惠婵, 张海红, 刘妙燕. 慢性肾小球肾病与糖尿病肾病维持血液透析患者的贫血对照研究[J]. 中国医药科学, 2012, 2(14): 197-199.
|
| [7] |
范秀芳, 王嘉佳, 刁建辉, 等. 糖尿病肾病与非糖尿病肾病贫血的对照研究[J]. 中国当代医药, 2015, 22(24): 35-37.
|
| [8] |
Camargo JL, Gross JL. Conditions associated with very low values of glycohaemoglobin measured by an HPLC method[J]. J Clin Pathol, 2004, 57(4): 346-349.
doi: 10.1136/jcp.2002.007088
pmid: 15047733
|
| [9] |
Kidney Disease: Improving Global Outcomes KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney Int Suppl, 2012, 2(4):279-335.
doi: 10.1038/ki.1972.107
URL
|
| [10] |
Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron[J]. Eur J Haematol, 2012, 89(1): 87-93.
doi: 10.1111/j.1600-0609.2012.01783.x
pmid: 22435497
|
| [11] |
Ueda N, Takasawa K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease[J]. Nutrients, 2018, 10(9): 1173.
doi: 10.3390/nu10091173
URL
|
| [12] |
Loutradis C, Skodra A, Georgianos P, et al. Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: a nested case-control study[J]. World J Nephrol, 2016, 5(4): 358-366.
doi: 10.5527/wjn.v5.i4.358
URL
|
| [13] |
中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
|
| [14] |
Kim SH, Lee KA, Jin HY, et al. The relationship between anemia and the initiation of dialysis in patients with type 2 diabetic nephropathy[J]. Diabetes Metab J, 2015, 39(3): 240-246.
doi: 10.4093/dmj.2015.39.3.240
pmid: 26124994
|
| [15] |
Toft G, Heide-Jørgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study[J]. J Nephrol, 2020, 33(1): 147-156.
doi: 10.1007/s40620-019-00652-9
pmid: 31587136
|
| [16] |
O’Mara NB. Anemia in patients with chronic kidney disease[J]. Diabetes Spectr, 2008, 21(1): 12-19.
doi: 10.2337/diaspect.21.1.12
URL
|
| [17] |
Aso Y, Suganuma R, Wakabayashi S, et al. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction[J]. Transl Res, 2009, 154(4):175-182.
doi: 10.1016/j.trsl.2009.07.005
pmid: 19766961
|
| [18] |
Tarng DC. Cardiorenal anemia syndrome in chronic kidney disease[J]. J Chin Med, 2007, 70(10):424-429.
|
| [19] |
Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD[J]. Am J Kidney Dis, 2013, 62(5): 849-859.
doi: 10.1053/j.ajkd.2013.06.008
pmid: 23891356
|
| [20] |
KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J]. Am J Kidney Dis, 2007, 49(2 Suppl 2):S12-S154.
doi: 10.1053/j.ajkd.2006.12.005
pmid: 17276798
|
| [21] |
Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease[J]. BMC Nephrol, 2017, 18(1):345.
doi: 10.1186/s12882-017-0688-1
pmid: 29191165
|
| [22] |
National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management[M/OL]. London: National Institute for Health and Care Excellence (NICE), 2021, https://www.nice.org.uk/guidance/ng203.
|
| [23] |
Panchapakesan U, Sumual S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)[J]. Int J Nanomedicine, 2007, 2(1): 33-38.
pmid: 17722510
|
| [24] |
Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease[J]. Diabetes Care, 2009, 32(7): 1320-1326.
doi: 10.2337/dc08-0779
pmid: 19564475
|
| [25] |
Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis[J]. Am J Kidney Dis, 2013, 61(1): 44-56.
doi: 10.1053/j.ajkd.2012.07.014
pmid: 22921639
|
| [26] |
Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease[J]. Clin Kidney J, 2016, 9(2): 260-267.
doi: 10.1093/ckj/sfv142
pmid: 26985378
|
| [27] |
Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease[J]. N Engl J Med, 2009, 361(21): 2019-2032.
doi: 10.1056/NEJMoa0907845
URL
|
| [28] |
Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study[J]. Am J Kidney Dis, 2007, 49(2):194-207.
doi: 10.1053/j.ajkd.2006.11.032
pmid: 17261422
|
| [29] |
Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022.
doi: 10.1056/NEJMoa1901713
URL
|
| [30] |
Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010.
doi: 10.1056/NEJMoa1813599
URL
|
| [31] |
Zhang L, Liu Y, Huang Y, et al. Effect of roxadustat versus erythropoietin(EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study[J]. Ann Transl Med, 2022, 10(22): 1224.
doi: 10.21037/atm-22-4344
pmid: 36544686
|
| [32] |
中国研究型医院学会肾脏病学专业委员会. 罗沙司他治疗肾性贫血中国专家共识[J]. 中华医学杂志, 2022, 102(24): 1802-1810.
|
| [33] |
Minutolo R, Garofalo C, Chiodini P, et al. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease[J]. Nephrol Dial Transplant, 2021, 36(2): 267-274.
doi: 10.1093/ndt/gfaa088
URL
|
| [34] |
Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD[J]. J Am Soc Nephrol, 2008, 19(8): 1599-605.
doi: 10.1681/ASN.2007101156
pmid: 18525001
|
| [35] |
Shukla R, Mishra N. Management of iron deficiency anemia-recent challenges[J]. Indian J Res, 2015, 4: 100-102.
|
| [36] |
中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018 修订版)[J]. 中华肾脏病杂志, 2018, 34(11): 860-866.
doi: 10.3760/cma.j.issn.1001-7097.2018.11.012
|
